Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
52.82 USD | -2.07% | -3.35% | -37.30% |
01:30pm | Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants | CI |
11/06 | Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.30% | 6.27B | |
+17.00% | 124B | |
+17.24% | 112B | |
+4.05% | 22.94B | |
-10.65% | 17.02B | |
-16.80% | 16.88B | |
-39.94% | 16.87B | |
+2.47% | 13.63B | |
+26.39% | 11.61B | |
+102.94% | 10.31B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating